Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due to an increase in revenue earned through the Company's strategic collaboration with Teva, as a result of the clinical development activities associated with the AFFINITY trial that was initiated in August 2012.
  • Total operating expenses for the three and nine months ended September 30, 2013 increased to $20.5 million and $49.6 million, respectively, compared to $14.9 million and $30.1 million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due primarily to increased clinical trial expenses associated with patient enrollment and treatment in the AFFINITY and Borealis-1 trials, increased costs related to the investigator-sponsored trials, increased employee expenses due to an increase in the number of employees to support our clinical development activities and increased toxicology expenses related to apatorsen and OGX-225.  These increases were partially offset by lower manufacturing costs due to the timing of apatorsen manufacturing activities.
  • Net loss for the three and nine months ended September 30, 2013 was $10.1 million, or $0.68 per diluted common share, and $25.2 million, or $1.72 per diluted common share, respectively. Net loss for the three and nine months ended September 30, 2012 was $5.9 million, or $0.40 per diluted common share, and $17.0 million, or $1.29 per diluted common share, respectively. The net loss in the nine months ended September 30, 2013 included a non-cash gain on revaluation of the warrant liability of $2.9 million compared with $2.5 million in the nine months ended September 30, 2012. 
  • The Company had $46.8 million in cash, cash equivalents and short-term investments as of September 30, 2013, compared to $75.4 million as of December 31, 2012.
  • 2013 cash guidance:
  • Net cash requirements are expected to be in the range of $40 - $50 million.

  • '/>"/>
    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
    3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
    4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/30/2015)... April 30, 2015 Available in ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative ... reactive skin while battling the weakening threat of ... cream is formulated with star ingredient GLYCOSEA, a ... in a complex of soothing minerals and trace ...
    (Date:4/30/2015)... Sterlitech is proud to offer Synder ... PY, and PZ Polyacrylonotrile (PAN) membranes , as ... to be ideal for oil removal in wastewater ... process requirements where the presence of oils in ... on industrial wastewater discharge and quality requirements for ...
    (Date:4/29/2015)... ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial statements ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , 1,703 ... 1,191 , 1,493 , 3,377 , ...
    (Date:4/29/2015)... Colo. , April 29, 2015 ... providers of cartilage, cellular, bone, skin and soft-tissue ... care to advance patient healing, announced the launch ... Centers for Medicare & Medicaid Services (CMS) also ... from the low-cost to the high-cost category for ...
    Breaking Biology Technology:Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Sterlitech Offers New Ultrafiltration Membranes 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4AlloSource Announces New Possibilities In Wound Care 2
    ... steps toward putting quantum computers into real practice sending ... and transmitting the signal to a second, distant qubit ... Yale. The accomplishments are reported in sequential issues of Nature ... highlighted as the cover along with complementary work from a ...
    ... 3% over Fiscal 2006 to $27.5 million - ... dollars unless otherwise noted), BELLEVILLE, ON, Sept. 26 ... technology-driven Canadian,biopharmaceutical company, today announced financial results for its ... announcements of the first shipment and commercial usage of,our ...
    ... Sept. 26 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ... in New York City on Thursday, October 4, 2007,from ... Westin New York at Times,Square, on 270 West 43rd ... C. Quay, M.D., Ph.D., Chairman, President and,Chief Executive Officer ...
    Cached Biology Technology:Yale scientists make 2 giant steps in advancement of quantum computing 2Yale scientists make 2 giant steps in advancement of quantum computing 3Bioniche Reports Fiscal 2007 Year-End Results 2Bioniche Reports Fiscal 2007 Year-End Results 3Bioniche Reports Fiscal 2007 Year-End Results 4Bioniche Reports Fiscal 2007 Year-End Results 5Bioniche Reports Fiscal 2007 Year-End Results 6Bioniche Reports Fiscal 2007 Year-End Results 7Bioniche Reports Fiscal 2007 Year-End Results 8Bioniche Reports Fiscal 2007 Year-End Results 9Bioniche Reports Fiscal 2007 Year-End Results 10Nastech to Host 2007 Analyst and Institutional Investor Day 2Nastech to Host 2007 Analyst and Institutional Investor Day 3
    (Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
    (Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
    (Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
    Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
    ... National Human Genome Research Institute has selected the Johns ... of Excellence" to study the ethical, legal and social ... will receive three years of funding to build on ... and public health, bringing the fields together in the ...
    ... HUNTSVILLE, TX (9/18/12) -- To help identify victims after ... or acts of genocide, researchers at Sam Houston State ... and speed up the DNA identification process. ... adverse conditions, such as remote locations, intense heat, and ...
    ... well to keep patients from developing AIDS, but no one ... the human body, so patients continue to require lifelong treatment ... team of researchers led by Dr. David N. Levy, Associate ... York University College of Dentistry (NYUCD), have discovered a new ...
    Cached Biology News:Personal genome, public health 2Personal genome, public health 3Sam Houston State studies DNA preservation in mass disasters 2New HIV-1 replication pathway discovered by NYU College of Dentistry researchers 2
    ... LM is a high quality microarray scanner based ... background rejection and spatial resolution. The DNAscope ... low cost microarray scanner that is upgradeable to ... Main Features: Includes control module (computer), ...
    ... Convenient, easy-to-use kits for arraying ... detection using common lab equipment. DiscoverLight ... analysis of your protein, cell lysate ... format. The kits include specially designed ...
    ... Stabilizer is an aqueous solution that ... other non-toxic stabilizing chemicals in a ... 6.5. This product contains ... 0.02% bromonitrodioxane as a preservative. ...
    ... When nonspecific binding is a problem ... variety of immobilized NeutrAvidin products as ... NeutrAvidin is a modified avidin derivative ... provide a biotin-binding protein with exceptionally ...
    Biology Products: